Business Context and Reporting Period
Company: Verrica Pharmaceuticals Inc. (VRCA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Verrica is a therapeutics company focused on dermatologic diseases. Its primary commercial product is YCANTH (VP-102), approved by the FDA in July 2023 for the treatment of molluscum contagiosum. The company is also developing YCANTH for common warts and VP-315 for basal cell carcinoma (BCC). As of December 31, 2025, the company had 76 full-time employees and a specialized sales force of approximately 40 representatives.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $35.6 million | $7.6 million |
| Product Revenue (Net) | $15.3 million | $6.6 million |
| License & Collaboration Revenue | $20.3 million | $1.0 million |
| Net Loss | $(17.9) million | $(76.6) million |
| Cash and Cash Equivalents (Year End) | $30.1 million | $46.3 million |
| Accumulated Deficit | $(324.9) million | $(307.0) million |
| Long-Term Debt | $0 (Extinguished) | $31.0 million |
Liquidity: The company reported cash and cash equivalents of $30.1 million as of December 31, 2025. Management believes this is sufficient to fund operations into the first quarter of 2027.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by $28.0 million (370%) year-over-year. This was driven primarily by a $19.3 million increase in license and collaboration revenue, resulting from $18.0 million in milestone payments from partner Torii Pharmaceutical Co., Ltd. (related to Japanese approval and Phase 3 program milestones). Product revenue also grew by $8.7 million due to increased deliveries of YCANTH.
- Reduced Net Loss: Net loss improved significantly from $76.6 million in 2024 to $17.9 million in 2025. This improvement was driven by higher revenue and a reduction in operating expenses.
- Expense Reductions: Selling, general, and administrative (SG&A) expenses decreased by $23.6 million to $35.2 million, largely due to a restructuring in late 2024 that reduced the sales force and eliminated non-sales roles. Research and development (R&D) expenses decreased by $3.0 million to $8.9 million, primarily due to lower clinical costs for VP-315.
- Debt Extinguishment: In November 2025, the company fully settled its $50.0 million credit facility with OrbiMed for $35.0 million, recognizing a $1.5 million loss on extinguishment. As of year-end, the company had no long-term debt.
- Capital Raise: In November 2025, the company completed a private placement raising net proceeds of $49.1 million through the sale of common stock, pre-funded warrants, and Series C warrants.
Guidance, Outlook, and Risks
Going Concern: The company has concluded that there is substantial doubt regarding its ability to continue as a going concern within one year after the date of the financial statements. While cash on hand is projected to last into Q1 2027, the company expects to continue incurring significant losses and will require additional financing to fund operations and development.
Outlook and Catalysts:
- YCANTH (Molluscum): Commercialization continues in the U.S. with a focus on market access (250 million covered lives). In Japan, partner Torii launched the product in February 2026. The company is exploring a Marketing Authorization Application for the European Union.
- YCANTH (Common Warts): A global Phase 3 clinical program with Torii commenced in late 2025, with the first patient dosed in December 2025. Costs are shared equally between Verrica and Torii.
- VP-315 (BCC): Following positive Phase 2 data and FDA feedback, the company is preparing for two Phase 3 studies. Data presented in November 2025 suggested a potential abscopal-like effect.
Risks and Contingencies:
- Capital Needs: The company is subject to "baby shelf" rules, limiting the amount of capital it can raise via Form S-3 until its public float exceeds $75 million. Failure to raise additional capital could force curtailment of operations.
- Competition: Zelsuvmi (berdazimer gel) was approved by the FDA in January 2024 and launched in July 2025, directly competing with YCANTH for molluscum.
- Supply Chain: The active pharmaceutical ingredient (cantharidin) is naturally sourced from beetles in China, creating supply chain and geopolitical risks.
- Legal Proceedings: A putative class action lawsuit regarding alleged manufacturing deficiencies was certified by the court in March 2026. Several derivative lawsuits were consolidated and stayed.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that $30.1 million in cash will sustain operations into Q1 2027, given the "substantial doubt" going concern qualification.
- Revenue Quality: Assess the sustainability of the $20.3 million in license revenue, which was heavily influenced by one-time milestone payments from Torii rather than recurring product sales.
- Debt Status: Confirm the complete extinguishment of the OrbiMed debt facility and the absence of new debt covenants.
- Competitive Landscape: Monitor market share data for YCANTH versus the newly launched competitor, Zelsuvmi, in the molluscum treatment market.
- Legal Exposure: Review the status of the certified class action lawsuit and potential financial impact of any settlement or judgment.
- Supply Chain Resilience: Evaluate the company's progress in developing synthetic cantharidin or alternative sourcing to mitigate reliance on Chinese natural sources.